Paper41420060
A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice.
Shi D and 13 others. Nat Microbiol, 2026. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice. Papers, record 41420060. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41420060
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Malaria Vaccines | Major topic |
| Nanoparticles | Major topic |
| Plasmodium falciparum | Major topic |
| Protozoan Proteins | Major topic |
| Malaria, Falciparum | Major topic |
| Malaria | Major topic |
| Animals | |
| Mice | |
| Antibodies, Protozoan | |
| Plasmodium vivax | |
| Female | |
| Disease Models, Animal | |
| Humans | |
| Sporozoites | |
| Mice, Inbred BALB C | |
| Nanovaccines |
Source PubMed
References85
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38341502 | Establishing RTS,S/AS01 as a benchmark for comparison to next-generation malaria vaccines in a mouse model. | NPJ Vaccines | 2024 | https://conductscience.org/library/papers/38341502 | PubMed |
| 2 | 30509385 | Molecular mimicry and autoimmunity. | J Autoimmun | 2018 | https://conductscience.org/library/papers/30509385 | PubMed |
| 3 | 10652487 | Field studies of cytotoxic T lymphocytes in malaria infections: implications for malaria vaccine development. | Parasitol Today | 2000 | https://conductscience.org/library/papers/10652487 | PubMed |
| 4 | 34632802 | Nano-carriers of COVID-19 vaccines: the main pillars of efficacy. | Nanomedicine (Lond) | 2021 | https://conductscience.org/library/papers/34632802 | PubMed |
| 5 | 28422178 | Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. | Sci Rep | 2017 | https://conductscience.org/library/papers/28422178 | PubMed |
| 6 | 33594061 | Structural and biophysical correlation of anti-NANP antibodies with in vivo protection against P. falciparum. | Nat Commun | 2021 | https://conductscience.org/library/papers/33594061 | PubMed |
| 7 | 23144750 | Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine. | PLoS One | 2012 | https://conductscience.org/library/papers/23144750 | PubMed |
| 8 | 23607541 | Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine. | Malar J | 2013 | https://conductscience.org/library/papers/23607541 | PubMed |
| 9 | 12438363 | A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. | Infect Immun | 2002 | https://conductscience.org/library/papers/12438363 | PubMed |
| 10 | 35360887 | Trapping and structural characterisation of a covalent intermediate in vitamin B6 biosynthesis catalysed by the Pdx1 PLP synthase. | RSC Chem Biol | 2022 | https://conductscience.org/library/papers/35360887 | PubMed |
| 11 | 17542753 | Virus-like particles: flexible platforms for vaccine development. | Expert Rev Vaccines | 2007 | https://conductscience.org/library/papers/17542753 | PubMed |
| 12 | 23142589 | Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. | Vaccine | 2012 | https://conductscience.org/library/papers/23142589 | PubMed |
| 13 | 23454164 | Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. | Lancet Infect Dis | 2013 | https://conductscience.org/library/papers/23454164 | PubMed |
| 14 | 30324137 | Cryo-EM structure of P. falciparum circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts. | Sci Adv | 2018 | https://conductscience.org/library/papers/30324137 | PubMed |
| 15 | 33815393 | Novel Virus-Like Particle Vaccine Encoding the Circumsporozoite Protein of Plasmodium falciparum Is Immunogenic and Induces Functional Antibody Responses in Mice. | Front Immunol | 2021 | https://conductscience.org/library/papers/33815393 | PubMed |
| 16 | 33964223 | Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. | Lancet | 2021 | https://conductscience.org/library/papers/33964223 | PubMed |
| 17 | 27647886 | Structural definition of the lysine swing in Arabidopsis thaliana PDX1: Intermediate channeling facilitating vitamin B6 biosynthesis. | Proc Natl Acad Sci U S A | 2016 | https://conductscience.org/library/papers/27647886 | PubMed |
| 18 | 27825348 | Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses. | Malar J | 2016 | https://conductscience.org/library/papers/27825348 | PubMed |
| 19 | 36410329 | The Importance of Exercising Caution When Comparing Results from Malaria Vaccines Administered on the EPI Schedule and on a Seasonal Schedule. | Am J Trop Med Hyg | 2022 | https://conductscience.org/library/papers/36410329 | PubMed |
| 20 | 26342424 | Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. | Lancet Infect Dis | 2015 | https://conductscience.org/library/papers/26342424 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42915742 | Protective-Antigen Scaffold Nanoparticle Vaccine Overcomes Carrier-Induced Suppression and Immunosenescence to Protect against Pseudomonas aeruginosa Pneumonia. | ACS Nano | 2026 | https://conductscience.org/library/papers/42915742 | PubMed |
| 42856535 | Protective near-germline antibodies to malaria elicited by RTS,S/AS01E vaccination in African infants. | bioRxiv | 2026 | https://conductscience.org/library/papers/42856535 | PubMed |
| 42476547 | Intelligent antigen design combined with yeast display enhances targeted immune responses. | Brief Bioinform | 2026 | https://conductscience.org/library/papers/42476547 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41420060
GET https://conductscience.org/api/papers/v1/41420060/references?page=2